Bupivacaine Patent Expiration

Bupivacaine is Used for providing local or regional analgesia in various surgical procedures and postoperative pain management. It was first introduced by Pacira Pharmaceuticals Inc in its drug Exparel on Oct 28, 2011. Another drug containing Bupivacaine is Posimir. 3 different companies have introduced drugs containing Bupivacaine.


Bupivacaine Patents

Given below is the list of patents protecting Bupivacaine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Exparel US11918565 Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions Feb 02, 2043 Pacira Pharms Inc
Exparel US11931459 Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions Mar 17, 2042 Pacira Pharms Inc
Exparel US11033495 Manufacturing of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Exparel US11179336 Manufacturing of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Exparel US11278494 Manufacturing of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Exparel US11304904 Manufacturing of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Exparel US11311486 Manufacturing of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Exparel US11357727 Manufacturing of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Exparel US11426348 Compositions of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Exparel US11452691 Compositions of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Exparel US11819574 Manufacturing of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Exparel US11819575 Manufacturing of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Exparel US11925706 Manufacturing of bupivacaine multivesicular liposomes Jan 22, 2041 Pacira Pharms Inc
Posimir US11400019 Sustained release drug delivery systems with reduced impurities and related methods Jan 12, 2041 Innocoll
Posimir US11771624 Sustained release drug delivery systems with reduced impurities and related methods Jan 12, 2041 Innocoll
Posimir US8153149 Controlled delivery system Sep 15, 2025 Innocoll
Posimir US8153661 Controlled delivery system Sep 15, 2025 Innocoll
Posimir US8753665 Controlled delivery system Sep 15, 2025 Innocoll
Posimir US8846072 Controlled delivery system Sep 15, 2025 Innocoll
Exparel US9585838 Production of multivesicular liposomes Dec 24, 2021

(Expired)

Pacira Pharms Inc
Exparel US8182835 Sustained-release liposomal anesthetic compositions Sep 18, 2018

(Expired)

Pacira Pharms Inc
Exparel US8834921 Sustained-release liposomal anesthetic compositions Sep 18, 2018

(Expired)

Pacira Pharms Inc
Exparel US9205052 Sustained-release liposomal anesthetic compositions Sep 18, 2018

(Expired)

Pacira Pharms Inc
Exparel US6132766 Multivesicular liposomes with controlled release of encapsulated biologically active substances Nov 16, 2013

(Expired)

Pacira Pharms Inc



Bupivacaine's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Bupivacaine Generic API Manufacturers

Several generic applications have been filed for Bupivacaine.

Given below is the list of companies who have filed for Bupivacaine generic, along with the locations of their manufacturing plants worldwide.


1. HENGRUI PHARMA

Jiangsu Hengrui Pharmaceuticals Co Ltd has filed for 2 different strengths of generic version for Bupivacaine. All of these versions come by the name BUPIVACAINE LIPOSOME. Given below are the details of the strengths of this generic introduced by Hengrui Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
133MG/10ML (13.3MG/ML)

injectable, liposomal Prescription INJECTION AP Jul 1, 2024
266MG/20ML (13.3MG/ML)

injectable, liposomal Prescription INJECTION AP Jul 1, 2024